Dexcom (DXCM) Research & Development (2010 - 2026)

Dexcom (DXCM) has reported Research & Development for 17 consecutive years, with $153.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development rose 3.24% year-over-year to $153.0 million in Q2 2026; TTM through Jun 2026 was $604.0 million, a 6.28% increase from a year earlier, with the FY2025 full-year figure at $599.1 million, up 8.45% from the prior year.
• Research & Development was $153.0 million for Q2 2026 at Dexcom, up from $145.3 million in the prior quarter.
• Over five years, Research & Development peaked at $157.5 million in Q3 2025 and troughed at $110.3 million in Q3 2022.
• A 5-year average of $135.5 million and a median of $136.0 million in 2023 frame the typical range for Research & Development.
• The widest YoY moves for Research & Development: up 24.22% in 2022, down 22.36% in 2022.
• Over 5 years, Research & Development stood at $116.3 million in 2022, then advanced by 17.02% to $136.1 million in 2023, then grew by 2.5% to $139.5 million in 2024, then gained by 6.24% to $148.2 million in 2025, then climbed by 3.24% to $153.0 million in 2026.
• The last three Research & Development figures came in at $153.0 million (Q2 2026), $145.3 million (Q1 2026), and $148.2 million (Q4 2025), per Business Quant data.